Talk:Histamine dihydrochloride

Treatment with Ceplene and IL-2 has been initiated in the UK as of the 20th of april 2010. It was introduced at the coinciding British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland, by EpiCepts commercial partner Meda AB. As of the 4th may of 2010 the fist commercial sale of Ceplene + IL-2 was evident due to a commercial sale initiation milestone payment received by EpiCept from it's commercial partner in the European Union, Meda AB.